Albert Bourla, Pfizer CEO (Evan Vucci/AP Images)
November 1, 2022 03:26 PM EDTUpdated 03:48 PM
Pharma

Amid rev­enue dip, Pfiz­er CEO Al­bert Bourla is fo­cused on 'what's nex­t'

Nicole DeFeudis

Editor

Pfiz­er suf­fered its first quar­ter­ly rev­enue dip since its BioN­Tech-part­nered Covid vac­cine was au­tho­rized in 2020, CEO Al­bert Bourla re­vealed on Tues­day. And if that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times